We’re tackling aging with the power of a global community

VitaDAO is a community-owned collective dedicated to funding and advancing longevity science that can improve people's lives. With your support we can turn the tide on age related disease.

Support for researchers

Connect with an active community of longevity scientists and get funding for your work.

Work With Us

Join the community

Contribute skills to help us advance longevity science. VitaDAO is owned and built by our community.

Contribute to the DAO

The VITA token

Everything you need to know about the governance token that powers our community

Discover VITA


Funding Deployed


Research Projects Funded


Liquid Funds


Community Members

17 Projects funded with $4 million
See All ProjectsSee all projects

IPNFTs & equity deals

Contribute to treasury

ImmuneAge Bio - Rejuvenation of aged HSCs

ImmuneAGE Bio is the first drug discovery platform company focused on immune system rejuvenation. ImmuneAGE rejuvenates hematopoietic stem cells (HSCs) from the bone marrow based on a geroscience screening platform enabled by a new ‘StemSupply’ method achieving >1000x expansion of HSCs.

View Project

ApoptoSENS - Senolytic CAR-NK Cells

Senescent cells accumulate with age and are associated with numerous diseases. Dr. Amit Sharma’s team have identified senescence-specific cell surface biomarkers which will act as targets for developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells aiming to precisely and safely eliminate senescent cells in vivo.

$ 253,000
View Project

Discovery of novel mitophagy activators for Alzheimer’s disease

Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.

$ 300,000
View Project

Scheibye-Knudsen Lab

What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.

$ 250,000
View Project

Non-profit initiatives

Make a donation

Support of Clinical Trial - The Effect of Regular Exercise & Intermittent Rapamycin Dosing


This clinical trial aims to investigate whether periods of time where the mechanistic target of Rapamycin (mTOR) pathway is activated via exercise, combined with alternate periods of time where mTOR is inhibited using Sirolimus (Rapamycin), will result in greater muscle performance in older adults compared with just exercise alone.

$ 50,000
View Project
Our Partners

Get involved today - support the science of tomorrow.

For Researchers

We support researchers at every stage of their career and provide funding to qualifying projects.

For Contributors

Help us build the world’s leading longevity DAO and get rewarded for your skills.

For Supporters

Beat age related disease by empowering the research bringing new therapeutics to market.

The VitaDAO Genesis hoodie is now available

Order now